ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 17

MPN Milestones of 2024 and What’s Next for 2025

, , , ,

Panelists discuss key accomplishments in the myeloproliferative neoplasm (MPN) space, highlighting pivotal developments that have shaped clinical practice, and share their excitement for 2025, including areas primed for significant progress and goals for the coming year.

EP. 1: Initial Treatment Strategies for Polycythemia Vera
EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
EP. 4: Interferon Therapy in PV
EP. 5: Safety Considerations for PV Therapy
EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
EP. 7: Interferon Real- World Treatment Patterns in PV
EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
EP. 10: An Overview to Myelofibrosis and Disease Risk
EP. 11: Treatment Goals for Myelofibrosis
EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials
EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
EP. 15: Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches
EP. 16: Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies
Now Viewing
EP. 17: MPN Milestones of 2024 and What’s Next for 2025

Video content above is prompted by the following:

  • What accomplishments in the MPN space are you most proud of? Which developments stand out as pivotal in shaping clinical practice?
  • What are you most excited about in 2025? What areas are primed for significant progress? What do you hope to achieve in the coming year?